Reference number : GC-2017-Q2-04382, amendment number : , agreement type : G, recipient legal name : Zenkina, Olena (University of Ontario Institute of Technology), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : The high adaptation ability of bacteria to existing antibacterial agents is a major issue that requires new_x000D_
approaches in the design of novel antibiotics. One such approach, used by a small hi-tech Canadian company_x000D_
Otava Ltd, is based on selective binding of chemical molecules to specific bacterial RNA or DNA sequences._x000D_
This binding leads to depletion of bacteria growth and reproduction. Here we propose a new methodology for_x000D_
chemical screening and evaluation of compounds designed to selectively bind microbial RNA/DNA. Using_x000D_
computer simulation methods, Otava Inc. has created novel libraries of fine organic compounds that match_x000D_
physical and structural parameters of typical RNA/DNA targets. Further screening steps aimed to determine_x000D_
the most promising pre-antibiotics are very expensive, time-consuming, and require special biohazard_x000D_
accredited laboratory facilities. For now, Otava Inc. needs to collaborate with large pharmaceutical companies_x000D_
to perform in vivo screening of the activity of each compound they produce. This approach significantly_x000D_
increases the turnover time between the development of the product and commercialization of the findings. The_x000D_
lack of the fast screening method to evaluate the activity of their compounds is hampering their research_x000D_
abilities and limiting their ability to grow. We believe that we will be able to develop a purely chemical method_x000D_
to estimate the potential of organic compounds from the library to act as selective inhibitors of duplication of_x000D_
specific bacterial DNA sequences. This will allow eliminating less effective compounds and proposing high_x000D_
quality competitive commercial products to the pharmaceutical industry. We expect this to allow the small_x000D_
Ontario company to grow and compete with larger international companies. It is not a secret that it is very_x000D_
difficult for Canadian companies to compete with third-world countries that over-use cheap labor power and_x000D_
maintain poor working environments to reduce the cost of their products. We want to use our scientific_x000D_
strengths to optimize the process of pharmaceutical screening and allow Canadian companies to intensify their_x000D_
research power while maintaining high standards of work environment and living., program purpose french : The high adaptation ability of bacteria to existing antibacterial agents is a major issue that requires new_x000D_
approaches in the design of novel antibiotics. One such approach, used by a small hi-tech Canadian company_x000D_
Otava Ltd, is based on selective binding of chemical molecules to specific bacterial RNA or DNA sequences._x000D_
This binding leads to depletion of bacteria growth and reproduction. Here we propose a new methodology for_x000D_
chemical screening and evaluation of compounds designed to selectively bind microbial RNA/DNA. Using_x000D_
computer simulation methods, Otava Inc. has created novel libraries of fine organic compounds that match_x000D_
physical and structural parameters of typical RNA/DNA targets. Further screening steps aimed to determine_x000D_
the most promising pre-antibiotics are very expensive, time-consuming, and require special biohazard_x000D_
accredited laboratory facilities. For now, Otava Inc. needs to collaborate with large pharmaceutical companies_x000D_
to perform in vivo screening of the activity of each compound they produce. This approach significantly_x000D_
increases the turnover time between the development of the product and commercialization of the findings. The_x000D_
lack of the fast screening method to evaluate the activity of their compounds is hampering their research_x000D_
abilities and limiting their ability to grow. We believe that we will be able to develop a purely chemical method_x000D_
to estimate the potential of organic compounds from the library to act as selective inhibitors of duplication of_x000D_
specific bacterial DNA sequences. This will allow eliminating less effective compounds and proposing high_x000D_
quality competitive commercial products to the pharmaceutical industry. We expect this to allow the small_x000D_
Ontario company to grow and compete with larger international companies. It is not a secret that it is very_x000D_
difficult for Canadian companies to compete with third-world countries that over-use cheap labor power and_x000D_
maintain poor working environments to reduce the cost of their products. We want to use our scientific_x000D_
strengths to optimize the process of pharmaceutical screening and allow Canadian companies to intensify their_x000D_
research power while maintaining high standards of work environment and living., agreement title english : Development of a novel technology for in vitro evaluation of RNA/DNA-targeted compounds, agreement title french : Development of a novel technology for in vitro evaluation of RNA/DNA-targeted compounds, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-09-20, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada